
Rapt Therapeutics to Showcase FLX475 Phase 1/2 Results at ESMO Immuno-Oncology Annual Congress
RAPT Therapeutics to Present FLX475 Phase 1/2 Data at the European Society for Medical Oncology Immuno-Oncology Congress Exciting News from RAPT Therapeutics SOUTH SAN FRANCISCO, Calif., Nov. 30, 2022 (GLOBE NEWSWIRE) — RAPT Therapeutics, Inc. (Nasdaq: RAPT) (“RAPT” or the “Company”), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule…